Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Therapeutic area

Reproductive system and breast disorders – page 6

  • 960 clinical trials
  • 390 recruiting
  • 346 conditions
  • 28 countries

Conditions in this area

346 conditions with trials, the busiest first

Breast cancer170Prostate cancer102Ovarian cancer90Breast cancer metastatic84Triple negative breast cancer69Hormone receptor positive HER2 negative breast cancer62Hormone-refractory prostate cancer56Endometrial cancer53Prostate cancer metastatic48HER2 positive breast cancer42Hormone receptor positive breast cancer42Cervix carcinoma35Fallopian tube cancer30Breast cancer female27Non-small cell lung cancer25Infertility female22Hormone-dependent prostate cancer19Infertility18Ovarian cancer recurrent18Ovarian epithelial cancer18Colorectal cancer12Gastric cancer12Head and neck cancer12Malignant peritoneal neoplasm12+322

Clinical trials in Reproductive system and breast disorders

960 trials across Europe, recruiting first

Type of trial
Recruitment status
Quick filters

960 clinical trials

Triple negative breast cancer

Recruiting

Study comparing datopotamab deruxtecan with or without durvalumab to chemotherapy with pembrolizumab for patients with triple-negative breast cancer

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:AstraZeneca AB

Ovarian endometrioid carcinoma

Recruiting

A Study Testing TUB-040 Combined with Standard Cancer Drugs for Patients with High-Grade Epithelial Serous or Endometrioid Ovarian Cancer

InvestigationalNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:TUB-040
  • Sponsor:Gilead Sciences Inc.

Prostate cancer

Recruiting

Study of How Enzalutamide and Apalutamide Affect Dexamethasone Processing in the Body in Patients with Prostate Cancer

Registered drugNo placebo
Countries:SwedenSweden
  • Participants:18–64 years · 65+ years
  • Substances:Apalutamide
  • Sponsor:Region Vaesterbotten

HER2 positive breast cancer

Recruiting

Testing 68Ga-NOTA-ABSCINT-HER2 Imaging to Predict Treatment Response in Patients with HER2-Positive Early Breast Cancer Receiving Chemotherapy

InvestigationalNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:68GA-NOTA-abscint-HER2
  • Sponsor:Centre Henri Becquerel

Hormone-refractory prostate cancer

Recruiting

A Study to Find a Safe Dose of TD001 for Patients with Metastatic Castration-Resistant Prostate Cancer that Expresses PSMA

InvestigationalNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Sponsor:T.O.A.D. Oncology S.A.

Endometrial cancer+6

Recruiting

A Study Testing BNT329 Safety and Effectiveness in Patients With Advanced Solid Tumors That Express the CA19-9 Tumor Marker

InvestigationalNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Sponsor:BioNTech SE

Ovarian cancer

Recruiting

A Study of Carboplatin Given Directly into the Abdomen After Surgery in Elderly and Frail Patients with Ovarian Cancer

Registered drugNo placebo
Countries:DenmarkDenmark
  • Participants:65+ years
  • Substances:Carboplatin
  • Sponsor:Odense University Hospital

Breast cancer+3

Recruiting

A study testing zanidatamab combined with chemotherapy before surgery in patients with HER2-positive breast cancer

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Jazz Pharmaceuticals Ireland Limited

Endometrial cancer

Recruiting

A Study of Inavolisib for Patients with Advanced Endometrial Cancer Who Have PIK3CA Gene Mutations

InvestigationalNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Inavolisib
  • Sponsor:IRCCS Istituto Nazionale Tumori Fondazione Pascale

Ovarian cancer

Recruiting

A Study of Mirvetuximab Soravtansine, Carboplatin, and Bevacizumab in Adults with Ovarian Cancer

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Bevacizumab
  • Sponsor:AbbVie Deutschland GmbH & Co. KG

Cervix carcinoma

Recruiting

A Study of Sacituzumab Tirumotecan, Pembrolizumab, and Bevacizumab for Patients with Metastatic Cervical Cancer That Has Spread or Returned

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Bevacizumab
  • Sponsor:Merck Sharp & Dohme LLC

Ovarian cancer

Recruiting

A Study of INCB123667 in Patients With Platinum-Resistant Ovarian Cancer That Has High Levels of Cyclin E1 Protein

InvestigationalNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:INCB123667
  • Sponsor:Incyte Corp.

Substances studied in this area

The therapies tested most often in Reproductive system and breast disorders trials.

Paclitaxel118 clinical trialsCarboplatin86 clinical trialsPembrolizumab76 clinical trialsLetrozole74 clinical trialsFulvestrant59 clinical trialsDocetaxel49 clinical trialsEnzalutamide49 clinical trialsExemestane47 clinical trialsAnastrozole45 clinical trials
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.